Abstract
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
GPI-Linked Proteins / antagonists & inhibitors
-
Genes, Neurofibromatosis 2
-
Genes, Tumor Suppressor*
-
Genes, p16
-
Humans
-
Immunotherapy*
-
Mesothelin
-
Mesothelioma / genetics*
-
Mesothelioma / metabolism
-
Mesothelioma / therapy*
-
Neovascularization, Pathologic / prevention & control*
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein-Arginine N-Methyltransferases / antagonists & inhibitors
-
Proto-Oncogene Proteins c-akt
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
Tumor Microenvironment
-
Tumor Suppressor Proteins / genetics
-
Ubiquitin Thiolesterase / genetics
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
BAP1 protein, human
-
GPI-Linked Proteins
-
Phosphoinositide-3 Kinase Inhibitors
-
Tumor Suppressor Proteins
-
PRMT5 protein, human
-
Protein-Arginine N-Methyltransferases
-
Proto-Oncogene Proteins c-akt
-
TOR Serine-Threonine Kinases
-
Ubiquitin Thiolesterase
-
Mesothelin